NURIX THERAPEUTICS, INC. Comprehensive Income
NURIX THERAPEUTICS, INC. (NRIX) reported Comprehensive Income of -$89.74 million for the 3-month period ending 2026-05-31, per its 10-Q filed 2026-07-09.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-07-09
- NURIX THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-05-31 was -$89.74M.
- NURIX THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-02-28 was -$87.22M.
- NURIX THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-11-30 was -$78.23M.
- NURIX THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-08-31 was -$86.28M.
- NURIX THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$264.50M.
- NURIX THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$192.76M.
- NURIX THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$140.28M.
- NURIX THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$184.07M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-05-31 | -$89.74M 10-Q · filed 2026-07-09 | -$176.96M 10-Q · filed 2026-07-09 | -$255.19M derived: sum of 3 quarters · filed 2026-07-09 | -$341.48M derived: sum of 4 quarters · filed 2026-07-09 |
| 2026-02-28 | -$87.22M 10-Q · filed 2026-04-08 | -$165.46M derived: sum of 2 quarters · filed 2026-04-08 | -$251.74M derived: sum of 3 quarters · filed 2026-04-08 | -$295.45M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-11-30 | -$78.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | -$164.52M derived: sum of 2 quarters · filed 2026-01-28 | -$208.23M derived: sum of 3 quarters · filed 2026-07-09 | -$264.50M 10-K · filed 2026-01-28 |
| 2025-08-31 | -$86.28M 10-Q · filed 2025-10-09 | -$129.99M derived: sum of 2 quarters · filed 2026-07-09 | -$186.27M 10-Q · filed 2025-10-09 | -$245.01M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-05-31 | -$43.71M 10-Q · filed 2026-07-09 | -$99.98M 10-Q · filed 2026-07-09 | -$158.73M derived: sum of 3 quarters · filed 2026-07-09 | -$207.21M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-02-28 | -$56.27M 10-Q · filed 2026-04-08 | -$115.02M derived: sum of 2 quarters · filed 2026-04-08 | -$163.50M derived: sum of 3 quarters · filed 2026-04-08 | -$207.83M derived: sum of 4 quarters · filed 2026-04-08 |
| 2024-11-30 | -$58.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | -$107.22M derived: sum of 2 quarters · filed 2026-01-28 | -$151.55M derived: sum of 3 quarters · filed 2026-01-28 | -$192.76M 10-K · filed 2026-01-28 |
| 2024-08-31 | -$48.48M 10-Q · filed 2025-10-09 | -$92.81M derived: sum of 2 quarters · filed 2025-10-09 | -$134.02M 10-Q · filed 2025-10-09 | -$175.40M derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-05-31 | -$44.33M 10-Q · filed 2025-07-09 | -$85.54M 10-Q · filed 2025-07-09 | -$126.93M derived: sum of 3 quarters · filed 2026-01-28 | -$163.23M derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-02-29 | -$41.21M 10-Q · filed 2025-04-08 | -$82.60M derived: sum of 2 quarters · filed 2026-01-28 | -$118.90M derived: sum of 3 quarters · filed 2026-01-28 | -$141.84M derived: sum of 4 quarters · filed 2026-01-28 |
| 2023-11-30 | -$41.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | -$77.69M derived: sum of 2 quarters · filed 2026-01-28 | -$100.62M derived: sum of 3 quarters · filed 2026-01-28 | -$140.28M 10-K · filed 2026-01-28 |
| 2023-08-31 | -$36.31M 10-Q · filed 2024-10-11 | -$59.24M derived: sum of 2 quarters · filed 2024-10-11 | -$98.90M 10-Q · filed 2024-10-11 | -$146.19M derived: sum of 4 quarters · filed 2025-01-28 |
| 2023-05-31 | -$22.93M 10-Q · filed 2024-07-11 | -$62.59M 10-Q · filed 2024-07-11 | -$109.89M derived: sum of 3 quarters · filed 2025-01-28 | -$156.25M derived: sum of 4 quarters · filed 2025-01-28 |
| 2023-02-28 | -$39.66M 10-Q · filed 2024-04-10 | -$86.95M derived: sum of 2 quarters · filed 2025-01-28 | -$133.32M derived: sum of 3 quarters · filed 2025-01-28 | -$179.74M derived: sum of 4 quarters · filed 2025-01-28 |
| 2022-11-30 | -$47.29M derived: 10-K 12 month − 10-Q 9 month · filed 2025-01-28 | -$93.66M derived: sum of 2 quarters · filed 2025-01-28 | -$140.08M derived: sum of 3 quarters · filed 2025-01-28 | -$184.07M 10-K · filed 2025-01-28 |
| 2022-08-31 | -$46.37M 10-Q · filed 2023-10-12 | -$92.79M derived: sum of 2 quarters · filed 2023-10-12 | -$136.78M 10-Q · filed 2023-10-12 | -$175.03M derived: sum of 4 quarters · filed 2023-10-12 |
| 2022-05-31 | -$46.42M 10-Q · filed 2023-07-13 | -$90.41M 10-Q · filed 2023-07-13 | -$128.66M derived: sum of 3 quarters · filed 2023-07-13 | -$157.59M derived: sum of 4 quarters · filed 2023-07-13 |
| 2022-02-28 | -$43.99M 10-Q · filed 2023-04-13 | -$82.24M derived: sum of 2 quarters · filed 2023-04-13 | -$111.17M derived: sum of 3 quarters · filed 2023-04-13 | -$137.57M derived: sum of 4 quarters · filed 2023-04-13 |
| 2021-11-30 | -$38.25M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | -$67.17M derived: sum of 2 quarters · filed 2023-02-09 | -$93.58M derived: sum of 3 quarters · filed 2023-02-09 | -$117.89M 10-K · filed 2023-02-09 |
| 2021-08-31 | -$28.92M 10-Q · filed 2022-10-06 | -$55.33M derived: sum of 2 quarters · filed 2022-10-06 | -$79.64M 10-Q · filed 2022-10-06 | -$99.60M derived: sum of 4 quarters · filed 2022-10-06 |
| 2021-05-31 | -$26.40M 10-Q · filed 2022-07-07 | -$50.71M 10-Q · filed 2022-07-07 | -$70.68M derived: sum of 3 quarters · filed 2022-07-07 | -$89.20M derived: sum of 4 quarters · filed 2022-07-07 |
| 2021-02-28 | -$24.31M 10-Q · filed 2022-04-08 | -$44.28M derived: sum of 2 quarters · filed 2022-04-08 | -$62.80M derived: sum of 3 quarters · filed 2022-04-08 | -$55.13M derived: sum of 4 quarters · filed 2022-04-08 |
| 2020-11-30 | -$19.96M derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | -$38.48M derived: sum of 2 quarters · filed 2022-01-28 | -$30.82M derived: sum of 3 quarters · filed 2022-01-28 | -$43.15M 10-K · filed 2022-01-28 |
| 2020-08-31 | -$18.52M 10-Q · filed 2021-10-14 | -$10.86M derived: sum of 2 quarters · filed 2021-10-14 | -$23.19M 10-Q · filed 2021-10-14 | -$36.71M derived: sum of 4 quarters · filed 2022-01-28 |
| 2020-05-31 | $7.66M 10-Q · filed 2021-07-13 | -$4.67M 10-Q · filed 2021-07-13 | -$18.19M derived: sum of 3 quarters · filed 2022-01-28 | -$20.62M derived: sum of 4 quarters · filed 2022-01-28 |
| 2020-02-29 | -$12.33M 10-Q · filed 2021-04-13 | -$25.85M derived: sum of 2 quarters · filed 2022-01-28 | -$28.28M derived: sum of 3 quarters · filed 2022-01-28 | |
| 2019-11-30 | -$13.52M derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | -$15.95M derived: sum of 2 quarters · filed 2022-01-28 | -$21.70M 10-K · filed 2022-01-28 | |
| 2019-08-31 | -$2.43M 10-Q · filed 2020-10-14 | -$8.18M 10-Q · filed 2020-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |